Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 4, 2025

Earnings live: Ulta stock pops, HPE falls with guidance in focus

View original at finance.yahoo.com
Earnings live: Ulta stock pops, HPE falls with guidance in focus The third quarter earnings season is winding down, and only a handful of major companies have yet to report results…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Celestial AI acquisition strengthens Marvell's position in fastest-growing AI datacenter infrastructure opportunities

    80% confidence
  • 83% of Q3 earnings surprises have been to the upside

    80% confidence
  • Expansion of value concept beyond $5 price point worked well for growth

    80% confidence
  • Many consumers' wallets are pressured and they are seeking value as we look ahead to the holiday season

    80% confidence
  • Sentiment toward food retailers seems to have soured over the past few months

    80% confidence
  • Q3 was exceptional quarter with existing customers expanding and net-new customer additions showing strength

    80% confidence
  • AI clusters now measured in hundreds of thousands of GPUs and soon millions, pushing interconnect complexity

    80% confidence
  • Street is underestimating CrowdStrike growth potential as AI Revolution beneficiary

    80% confidence
  • All consumers are seeking value, and Dollar Tree thrives at intersection of value-seeking behavior with convenience and discovery

    80% confidence
  • Five Below saw nice traffic growth and growth in both new customers and retention

    80% confidence
  • Strong momentum continued into Q4 including excellent start to holiday season with record-breaking Thanksgiving weekend

    80% confidence
  • Companies that miss earnings saw stock decrease by 5% on average vs 2.6% five-year average

    80% confidence
  • Ulta is confident in plans to drive excitement and deliver for guests during holiday season

    80% confidence
  • Snowflake partnership is meaningful step toward making frontier AI genuinely useful for businesses

    80% confidence
  • Consumer and competitive environment has grown notably tougher for food retailers like Kroger

    80% confidence
  • Analysts expect 13.4% jump in S&P 500 EPS during Q3 2025

    80% confidence
  • Q3 sales were strongest in 13 quarters, reflecting acceleration of Bold New Chapter strategy

    80% confidence
  • Q2 results are strongest in Credo's history, reflecting AI training and inference cluster build-out

    80% confidence
  • 95% of S&P 500 companies have reported Q3 earnings as of Nov 21, 2025

    80% confidence
  • Enterprises want AI that can work within their secure data environments without compromise

    80% confidence
  • S&P 500 companies that beat earnings saw stock increase by 0.4% on average vs 0.9% five-year average

    80% confidence

Data points we hold from this source

Snowflake Inc. · product revenue guidance1.19-1.2 billion_USD
Snowflake Inc. · revenue guidance4.44 billion_USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com